文献速递临床试验与 GCP基础与转化研究

中等或远端血管闭塞缺血性卒中的机械取栓:DISCOUNT随机临床试验

Mechanical Thrombectomy in Ischemic Stroke With a Medium or Distal Arterial Occlusion: The DISCOUNT Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

DISCOUNT试验在法国22个卒中中心随机纳入244例因原发孤立中等或远端血管闭塞(MDVO)所致急性缺血性卒中患者,比较取栓联合药物治疗与单纯药物治疗。因无效且取栓组症状性颅内出血增加,试验经计划中期分析后提前终止。3个月良好临床结局取栓组62% vs 对照组68%(OR 0.73,95%CI 0.40-1.31;

要点

  • MDVO所致急性缺血性卒中取栓未提高3个月良好结局率(62% vs 68%)。
  • 实际接受取栓者症状性颅内出血(11% vs 3%)及蛛网膜下腔出血(13% vs 2%)更高。

核心结论

  • 对于原发孤立中等或远端血管闭塞所致急性缺血性卒中,取栓联合药物治疗未较单纯药物治疗提高3个月良好临床结局率。
  • 取栓后出血并发症更频繁,试验因无效及症状性颅内出血增加而提前终止。

研究设计与样本

  • 法国22个卒中中心开展的随机临床试验,计划纳入488例,实际随机244例。
  • 纳入标准:症状发作8小时内或最后正常时间24小时内且FLAIR无高信号的原发孤立MDVO所致急性缺血性卒中成人患者。
  • 干预:取栓联合药物治疗(n=123) vs 单纯药物治疗(n=121)。
  • 主要终点:3个月改良Rankin量表评分0-2分(良好临床结局),由独立盲法评估者评定。

主要发现

  • 244例随机患者中位年龄75岁(IQR 67-81),56%男性,中位NIHSS评分8分(IQR 6-12)。
  • 取栓组123例中100例(81%)实际接受取栓,对照组121例中无接受取栓;217例(89%)完成随访。

临床怎么用

  • 对于原发孤立MDVO所致急性缺血性卒中,取栓不应作为常规推荐,需权衡出血风险。
  • 临床决策应个体化,关注取栓后症状性颅内出血及蛛网膜下腔出血风险。

局限性

  • 试验因无效及症状性颅内出血增加经计划中期分析后提前终止,实际样本量244例低于计划488例。
  • 取栓组仅81%实际接受取栓,存在交叉与未治疗情况。
  • 随访完成率89%,部分患者主要终点缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Evidence regarding efficacy and safety of thrombectomy in acute ischemic stroke (AIS) due to medium or distal vessel occlusions (MDVOs) is lacking. OBJECTIVE: To evaluate the benefit of thrombectomy, in addition to medical treatment over medical treatment alone, in patients with an AIS related to a primary and isolated MDVO. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial conducted at 22 stroke centers in France from November 2021 to April 2025, with planned enrollment of 488 patients. The trial has been stopped after the planned interim analysis on the recommendation of the data and safety monitoring board for futility and increased rate of symptomatic intracranial hemorrhage with thrombectomy. Eligible adult patients had an AIS due to a primary MDVO within 8 hours of symptom onset or within 24 hours of last seen well if no hyperintense signal was present on fluid-attenuated inversion recovery imaging. INTERVENTION: Thrombectomy in addition to medical treatment (n = 123) or medical treatment alone (n = 121). MAIN OUTCOMES AND MEASURES: The primary end point was a good clinical outcome at 3 months, defined as a modified Rankin Scale score of 0 to 2, assessed by an independent, blinded assessor. Secondary end points included mortality rate at 3 months and adverse and serious adverse events. RESULTS: Of the 244 patients randomized (median age, 75 years [IQR, 67-81]; 56% male; median National Institutes of Health Stroke Scale score, 8 [IQR, 6-12]), 100 of the 123 patients in the thrombectomy group (81%) received thrombectomy and none of the 121 patients in the control group received thrombectomy; 217 (89%) completed follow-up. At 3 months, 72 of 116 patients (62%) in the thrombectomy group had a good clinical outcome vs 81 of 119 patients (68%) in the control group (odds ratio, 0.73 [95% CI, 0.40-1.31]; P = .29; adjusted absolute difference, -6.8% [95% CI, -19.4% to 5.7%]). The incidence of symptomatic intracranial hemorrhages was higher among the 100 patients who actually received thrombectomy than in those who did not (11% vs 3%, P = .008), as was incidence of subarachnoid hemorrhages (13% vs 2%, P < .001) and embolus migration (5% vs 1%, P = .04). Mortality rate did not significantly differ between the 2 groups (6% vs 8%; P = .49). CONCLUSIONS AND RELEVANCE: Thrombectomy did not lead to a higher rate of good clinical outcome at 3 months compared with medical treatment alone in patients with acute ischemic stroke related to an MDVO. Hemorrhagic complications were more frequent after thrombectomy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05030142.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Clarençon F, Bala F, Baptiste A, et al. Mechanical Thrombectomy in Ischemic Stroke With a Medium or Distal Arterial Occlusion: The DISCOUNT Randomized Clinical Trial. JAMA. 2026. PMID: 42485024. doi:10.1001/jama.2026.8977

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。